Small Trial of Alendronate Impact on the Reservoir of HIV

Part of paid clinical trials in San Francisco, California.

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Study ID
NCT07216794
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Alendronate — DRUG
    70 mg oral capsules
  • Placebo — OTHER
    Matching ALN placebo oral capsules

Study Details

This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.

Key Dates

Start date
Jun 27, 2026
Status verified
Jun 2026
Primary completion
Mar 26, 2027
Completion
May 21, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Alendronate
  • Placebo Comparator: Arm B: Placebo

Primary Outcome Measure

Change in intact HIV-1 deoxyribonucleic acid (DNA) copies by the Intact Proviral DNA Assay (IPDA) in peripheral blood [ Time Frame: Baseline to week 24 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
University of California, San Francisco HIV/AIDS (Site ID: 801)San FranciscoCalifornia94110
Jay Dwyer
[email protected]
415-502-5748
University of Colorado Hospital (Site ID: 6101)AuroraColorado80045
Nicola Haakonsen
[email protected]
303-724-5931
Chapel Hill (Site ID: 3201)Chapel HillNorth Carolina27599
Erin Hoffman
[email protected]
919-843-0720
Ohio State University (Site ID: 2301)ColumbusOhio43210
Lindsay Summers
[email protected]
614-293-8529
University of Pittsburgh (Site ID: 1001)PittsburghPennsylvania15213
Stacey M. Edick
[email protected]
412-383-1748

Find similar trials in San Francisco, CA

By condition
HIV
By specialty
Infectious disease
By research site
University of California, San Francisco HIV/AIDS (Site ID: 801)· San Francisco, CAUniversity of Colorado Hospital (Site ID: 6101)· Aurora, COChapel Hill (Site ID: 3201)· Chapel Hill, NCOhio State University (Site ID: 2301)· Columbus, OHUniversity of Pittsburgh (Site ID: 1001)· Pittsburgh, PA

Related Studies